AbbVie (ABBV) Total Non-Current Liabilities (2012 - 2026)

AbbVie has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $109.0 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 2.66% year-over-year to $109.0 billion; the TTM figure through Mar 2026 stood at $109.0 billion (down 2.66% YoY), while the FY2025 annual figure was $104.7 billion, down 4.97% from the prior year.
• Total Non-Current Liabilities improved to $109.0 billion in Q1 2026, from $104.7 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ABBV reached as high as $120.7 billion in Q1 2024 and fell as low as $103.3 billion in Q1 2023.
• The 5-year median for Total Non-Current Liabilities is $109.0 billion (2026), against an average of $109.1 billion.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities dropped 9.53% — and 2024, when it climbed 16.8%.
• A 5-year view of Total Non-Current Liabilities shows it stood at $105.1 billion in 2022, then dropped by 0.68% to $104.4 billion in 2023, then gained by 5.47% to $110.1 billion in 2024, then fell by 4.97% to $104.7 billion in 2025, then grew by 4.15% to $109.0 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $109.0 billion, $104.7 billion, and $104.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.